Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654882 · ClinicalTrials.gov registry record · Phase 3
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
A Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA), sponsored by Duke University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 5
- Study locations
NCT06654882: Recruiting Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA), sponsored by Duke University.
NCT06654882 is a Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) that is actively recruiting participants, run by Duke University. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654882, a Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
Primary Outcome
Minimal disease activity (MiDA) at Month 6 as assessed by the cJADAS10 ≤5 MiDA is low-disease activity and inactive disease in this protocol. Score range for the cJADAS10 (total): 0 - 30. Disease State cJADAS10 Score Inactive disease ≤2.5 Low-disease activity 2.6 - 5 Moderate-disease activity 5.1 - 16 High-disease activity \>16 Minimal disease activity (MiDA) is a state of low disease activity or remission that is considered a useful treatment target for both patients and physicians. The cl
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Tocilizumab
- DRUG TNFi (Tumor Necrosis Factor inhibitor) medication
- DRUG Tofacitinib
Study Locations (5)
California
- University of California San Francisco Pediatric Rheumatology - San Francisco
Florida
- University of Florida - Gainesville
New Jersey
- Hackensack University Medical Center - Joseph M. Sanzari Children's Hospital - Hackensack
Ohio
- Nationwide Children's Hospital - Columbus
North Rhine-Westphalia
- Asklepios Children's Hospital - Sankt Augustin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT06654882 shows while recruiting
NCT06654882 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Polyarticular Course Juvenile Idiopathic Arthritis (JIA) appearing as the primary indexed condition, and to 4 interventions - of which Abatacept is the first listed.
NCT06654882 lists 5 locations in 5 states (California, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06654882 about?
NCT06654882 is a clinical study titled "Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis". This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages cor...
What is the current status of trial NCT06654882?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2026-01-09. Estimated completion is 2026-12.
What conditions does trial NCT06654882 study?
This clinical trial studies the following conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA).
What interventions are being tested in trial NCT06654882?
The interventions under investigation include: Abatacept (DRUG), Tocilizumab (DRUG), TNFi (Tumor Necrosis Factor inhibitor) medication (DRUG), Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT06654882?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06654882 being conducted?
This trial has 5 study locations across California, Florida, New Jersey, Ohio, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06654882's enrollment target sits among peer trials
400 923rd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI